Compare Amylx Pharmaceuticals Inc (AMLX) vs Prudential Financial Inc (PRU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Prudential Financial Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Prudential Financial Inc trades at $115.48 (market cap $40.07B). The key difference: Prudential Financial Inc is far larger — about 20.2× Amylx Pharmaceuticals Inc's market cap, and Prudential Financial Inc pays a 4.85% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PRU | |
|---|---|---|
Market Cap | $1.98B | $40.07B |
Sector | Health | Financials |
52-Week High | $18.70 | $118.72 |
52-Week Low | $7.64 | $92.00 |
Enterprise Value | $1.70B | $67.13B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
PRU trades at $115.37, up 0.32% on the day, with a bullish technical signal and strong support at $113. The stock shows solid fundamentals with a P/E of 11.88 and net income margin of 5.5%, while recent earnings beats in Q1 2026 and dividend announcements highlight financial stability. News coverage emphasizes expansion in retirement products and international markets.
Outlook remains positive given valuation discounts and earnings momentum, though risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, but the stock's current technical strength and fundamental metrics support a steady growth trajectory for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
